Skye Bioscience, Inc. (SKYE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Skye Bioscience reported revenue of $0. Net income was -$55.9M, or -$11.28 per diluted share. Operating activities generated -$43.1M of cash, leaving -$43.1M of free cash flow. At fiscal year end, Skye Bioscience held $28.3M in total assets against $8.3M in total liabilities, including $5.9M of cash and equivalents.
Open the full interactive Skye Bioscience financials → Quarterly statements, key ratios, valuation history and price charts.
Skye Bioscience Key Stats
| Share Price | $1.53 |
|---|---|
| Market Cap | $7.6M |
| 52-Week Range | $1.53 – $12.88 |
| Shares Outstanding | 5.0 million (basic, 2026 Q2) |
Skye Bioscience Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$6.3M | -$7.8M | -$18.3M | -$34.7M | -$30.2M | -$58.2M |
| Pre-Tax Income | -$6.6M | -$8.5M | -$19.5M | -$37.6M | -$26.6M | -$55.9M |
| Income Tax | $1,600 | $2,100 | $6,741 | $3,600 | $10,071 | $5,400 |
| Net Income | -$6.6M | -$8.5M | -$19.5M | -$37.6M | -$26.6M | -$55.9M |
| Diluted EPS | -$60.00 | -$40.00 | -$80.00 | -$42.96 | -$5.84 | -$11.28 |
Skye Bioscience Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$12.8M | -$14.4M | -$12.5M | -$10.8M |
| Diluted EPS | -$2.56 | -$0.36 | -$2.56 | -$2.16 |
Skye Bioscience Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | — | — | — | $68.4M | $5.9M |
| Current Assets | $2.7M | $9.6M | $8.9M | $11.7M | $70.8M | $27.1M |
| Total Assets | $2.7M | $9.9M | $9.1M | $11.9M | $72.8M | $28.3M |
| Current Liabilities | $787,199 | $3.9M | $12.1M | $13.9M | $4.3M | $8.2M |
| Total Long-Term Debt | $1.4M | — | — | — | — | — |
| Total Liabilities | $2.2M | $4.0M | $12.1M | $14.1M | $4.6M | $8.3M |
| Shareholders' Equity | $450,786 | $5.9M | -$3.0M | -$2.1M | $68.2M | $20.0M |
Skye Bioscience Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$6.1M | -$6.5M | -$12.7M | -$14.0M | -$25.2M | -$43.1M |
| Cash From Investing | -$7,230 | -$90,866 | $5.2M | $6.6M | -$245,615 | -$19.5M |
| Cash From Financing | $6.7M | $13.1M | -$208,794 | $16.4M | $83.6M | $29,571 |
| Free Cash Flow | -$6.1M | -$6.6M | -$12.8M | -$14.0M | -$26.8M | -$43.1M |
Figures from Skye Bioscience's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Skye Bioscience financials page for every line item.
Skye Bioscience Company Profile
| Ticker | SKYE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001516551 |
Frequently Asked Questions
What was Skye Bioscience's revenue in fiscal 2025?
Skye Bioscience (SKYE) reported revenue of $0 for fiscal 2025.
What is Skye Bioscience's annual revenue history?
Skye Bioscience's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Skye Bioscience's net income in fiscal 2025?
Skye Bioscience reported net income of -$55.9M for fiscal 2025.
What was Skye Bioscience's earnings per share (EPS) in fiscal 2025?
Skye Bioscience's diluted EPS was -$11.28 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Skye Bioscience generate in fiscal 2025?
Skye Bioscience generated -$43.1M of free cash flow in fiscal 2025.
What was Skye Bioscience's revenue last quarter?
In its most recent reported quarter (2026 Q2), Skye Bioscience reported revenue of $0.
How many shares of Skye Bioscience are outstanding?
Skye Bioscience reported a weighted average of 5.0 million basic shares outstanding in 2026 Q2.
What is Skye Bioscience's market cap?
Based on its latest closing price, Skye Bioscience (SKYE) has a market capitalization of about $7.6M.
When does Skye Bioscience's fiscal year end?
Skye Bioscience's fiscal year end, as registered with the SEC, is December 31.
Where is Skye Bioscience headquartered?
Skye Bioscience lists its business address in San Diego, California in its SEC filings.